Skip to content

Enterprise value at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$158.92B-2.6%
Inhibrx Biosciences, Inc. logo
Inhibrx Biosciences, Inc.INBX
$1B+982%
Corvus Pharmaceuticals logo
Corvus PharmaceuticalsCRVS
$1.19B+459%
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX
$8.16B+187%
Avalo Therapeutics logo
Avalo TherapeuticsAVTX
$315.24M+909%
Janux Therapeutics logo
Janux TherapeuticsJANX
$815.3M-47.2%

Other financials

Income statement

See full
Revenue-
Net income-$7.5M-13.1%
EPS (diluted)-$0.13+13.3%

Balance sheet

See full
Cash & equivalents$6.3M+1.3%
Total debt$456.9K+178%
Total equity$23.2M+135%
Total assets$29.7M+103%

Cash flow

See full
Operating cash flow-$4.4M+6.9%
CapEx$48.8K+14.5%
Free cash flow-$4.5M+6.7%

Valuation

See full
Market cap$155.39M+45.8%

Returns & leverage

See full
Return on equity-187.2%
Debt / equity0.0×
Current ratio1.2×-1.8×

Where this comes from

Calculated from TuHURA Biosciences, Inc.’s reported figures.

The official record: TuHURA Biosciences, Inc.’s 10-Q, filed May 15, 2026, on SEC EDGAR. View the filing →

Ask your AI about TuHURA Biosciences, Inc.'s enterprise value.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is TuHURA Biosciences, Inc.'s enterprise value?
TuHURA Biosciences, Inc. (HURA) reported enterprise value of $95.25M in Q1 2026.
How has TuHURA Biosciences, Inc.'s enterprise value changed year-over-year?
TuHURA Biosciences, Inc.'s enterprise value decreased by 27.1% year-over-year, from $130.64M to $95.25M.
What does enterprise value mean?
Market capitalization plus total debt minus cash, at the quarter end. The cost to acquire the whole business — what an buyer pays for equity and debt, net of the cash they'd inherit.